Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.4 EUR
−107.52 M EUR
68.87 M EUR
66.61 M
About Zymeworks Inc.
Sector
CEO
Kenneth Harry Galbraith
Headquarters
Middletown
Website
Founded
2003
FIGI
BBG01B0MBB35
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ZYMEWORKS DL-,00001 stocks are traded under the ticker ZA8.
We've gathered analysts' opinions on ZYMEWORKS DL-,00001 future price: according to them, ZA8 price has a max estimate of 29.16 EUR and a min estimate of 11.66 EUR. Watch ZA8 chart and read a more detailed ZYMEWORKS DL-,00001 stock forecast: see what analysts think of ZYMEWORKS DL-,00001 and suggest that you do with its stocks.
Yes, you can track ZYMEWORKS DL-,00001 financials in yearly and quarterly reports right on TradingView.
ZYMEWORKS DL-,00001 is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
ZA8 earnings for the last quarter are −0.35 EUR per share, whereas the estimation was −0.36 EUR resulting in a 1.71% surprise. The estimated earnings for the next quarter are −0.10 EUR per share. See more details about ZYMEWORKS DL-,00001 earnings.
ZYMEWORKS DL-,00001 revenue for the last quarter amounts to 14.37 M EUR, despite the estimated figure of 16.08 M EUR. In the next quarter, revenue is expected to reach 43.66 M EUR.
ZA8 net income for the last quarter is −26.81 M EUR, while the quarter before that showed −35.18 M EUR of net income which accounts for 23.80% change. Track more ZYMEWORKS DL-,00001 financial stats to get the full picture.
No, ZA8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 18, 2025, the company has 277.00 employees. See our rating of the largest employees — is ZYMEWORKS DL-,00001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ZYMEWORKS DL-,00001 EBITDA is −98.95 M EUR, and current EBITDA margin is −158.85%. See more stats in ZYMEWORKS DL-,00001 financial statements.
Like other stocks, ZA8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZYMEWORKS DL-,00001 stock right from TradingView charts — choose your broker and connect to your account.